Undersøgelsen skal desuden omfatte prostatacancer- undergrupper bestående af patienter, der behandles med bicalutamid, med GnRH- analoger, med orkiektomi eller med anden hormonbehandling.
Further, the study should include prostate cancer subgroups to include those on bicalutamide, and those treated with LHRH analogues, orchidectomy, and other hormonal therapies.